Regeneron officer files $1.0M stock sale notice

An officer of Regeneron Pharmaceuticals filed a Rule 144 notice to sell up to 1,215 REGN common shares via UBS, tied to prior restricted stock vesting.

Rhea-AI Filing Summary

REGENERON PHARMACEUTICALS, INC. (REGN) reports that company officer Marion McCourt has filed a notice under Rule 144 to sell up to 1,215 shares of Regeneron common stock through UBS Financial Services Inc. on or after September 2, 2026 on NASDAQ. The shares relate to vested restricted stock awards from February 12, 2023, December 9, 2024, and December 16, 2024, with an aggregate value of $1,032,750 reported in the notice.

Key Figures

Shares to be sold: 1,215 shares Aggregate value of shares: $1,032,750 Approximate sale date: September 2, 2026 +3 more

6 metrics

Shares to be sold 1,215 shares Maximum Regeneron common shares covered by the Rule 144 notice

Aggregate value of shares $1,032,750 Reported aggregate value of the 1,215 shares covered by the notice

Approximate sale date September 2, 2026 Listed as the approximate date of sale for the shares

RSA vesting shares on February 12, 2023 224 shares Common stock from RSA vesting by the issuer on February 12, 2023

RSA vesting shares on December 9, 2024 263 shares Common stock from RSA vesting by the issuer on December 9, 2024

RSA vesting shares on December 16, 2024 728 shares Common stock from RSA vesting by the issuer on December 16, 2024

Key Terms

Rule 144, RSA Vesting, attorney-in-fact

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

RSA Vesting financial

"Common | 02/12/2023 | RSA Vesting | Issuer"

attorney-in-fact regulatory

"UBS Financial Services Inc, as attorney-in-fact for Marion McCourt"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing report for REGN?

It reports that officer Marion McCourt has filed a Rule 144 notice to sell up to 1,215 shares of Regeneron Pharmaceuticals, Inc. common stock through UBS Financial Services Inc., with NASDAQ listed as the trading market.

How many REGN shares are covered by this Form 144 notice?

The notice covers up to 1,215 shares of Regeneron Pharmaceuticals, Inc. common stock, with an aggregate reported value of $1,032,750 at the time of the filing.

When may the REGN shares be sold under this Form 144?

The notice lists an approximate sale date of September 2, 2026 for the potential sale of up to 1,215 shares of Regeneron Pharmaceuticals, Inc. common stock under Rule 144.

How were the REGN shares in this Form 144 acquired?

The shares are tied to restricted stock award (RSA) vesting events from the issuer, Regeneron Pharmaceuticals, Inc., on February 12, 2023 (224 shares), December 9, 2024 (263 shares), and December 16, 2024 (728 shares).

Which broker is listed for the potential REGN share sale?

The notice lists UBS Financial Services Inc., located at 11 Madison Ave, New York, as the broker for the potential sale of up to 1,215 shares of Regeneron common stock.

Who signed the Form 144 related to REGN?

The Form 144 is signed “/s/ UBS Financial Services Inc, as attorney-in-fact for Marion McCourt,” indicating UBS executed the filing on behalf of the officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:11 PM EDT Accepted by SEC EDGAR 09/02/2026 - 04:11 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001663758
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	REGENERON PHARMACEUTICALS, INC.
SEC File Number	000-19034
Address of Issuer	777 OLD SAW MILL RIVER ROAD TARRYTOWN NEW YORK 10591
Phone	9148477000
Name of Person for Whose Account the Securities are To Be Sold	McCourt Marion
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc. 11 Madison Ave 4th Floor New York NY 10010	1215	1032750.00	101137842	09/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/12/2023	RSA Vesting	Issuer			224	02/12/2023	N/A
Common	12/09/2024	RSA Vesting	Issuer			263	12/09/2024	N/A
Common	12/16/2024	RSA Vesting	Issuer			728	12/16/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/17/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for Marion McCourt
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)